Answers are grounded in this paper and cite their sources.
Cross-sectional study identifies F8 Inv22 prevalence in severe haemophilia A, suggesting testing implications.
INTRODUCTION: Haemophilia A (HA) is caused by an inherited deficiency of factor VIII. Intron 22 inversion is the most common genetic mutation that causes severe disease. The study aims to determine the prevalence of F8 Inv22 in patients with severe HA and to compare demographic, haematological and clinical features among patients with and without intron Inv22. METHODS: This cross-sectional study included male HA patients with FVIII: C ≤1 IU/dL from the Pakistan Hemophilia Welfare Association Lahore centre during July 2023 to August 2024. IS-PCR technique was used to analyse Inv22. It amplified circular DNA molecules from a complex mix of DNA fragments. Data were analysed using SPSS version 24. RESULTS: The prevalence of Intron 22 inversion among 97 severe HA patients was found to be 40%. The mean age of patients with Intron 22 inversion and without the inversion was 20.17 ± 11.1 and 20.52 ± 12.0 years, respectively. The mean FVIII level was 0.28 ± 0.117 IU/dL in patients with Intron Inv22 and 0.77 ± 0.133 IU/dL in patients without the inversion. The difference in FVIII levels between the two groups was found to be statistically significant. The mean ISTH-BAT score among Inv22-positive patients (15.2 ± 5.2) was higher than Inv22-negative group (13.1 ± 4.2). The other haematological parameters like RBCs, WBCs and platelets did not differ significantly. CONCLUSION: Inv22 was present in 40% of the severe HA patients, and was associated with significantly lower FVIII levels and higher ISTH-BAT scores. These findings could be helpful in planning the molecular testing programs in similar resource constrained settings.
No takes yet. Share an insight, caveat, or question.
Mughal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: